Qualigen Therapeutics (QLGN) 10-Q 14 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 10, 2023
Entity Addresses [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-37428
Entity Registrant Name	Qualigen Therapeutics, Inc.
Entity Central Index Key	0001460702
Entity Tax Identification Number	26-3474527
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	5857 Owens Avenue
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92008
City Area Code	(760)
Local Phone Number	452-8111
Title of 12(b) Security	Common Stock, par value $.001 per share
Trading Symbol	QLGN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,181,058
Former Address [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	2042 Corte Del Nogal
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92011

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash	$ 2,073,849	$ 3,165,985
Prepaid expenses and other current assets	1,375,730	1,366,704
Current assets of discontinued operations		6,287,849
Total current assets	3,449,579	10,820,538
Property and equipment, net		26,242
Other assets	866,481
Non-current assets of discontinued operations		8,236,711
Total Assets	4,316,060	19,083,491
Current liabilities
Accounts payable	1,571,831	619,568
Accrued vacation	163,701	165,040
Accrued expenses and other current liabilities	1,144,188	699,519
Warrant liabilities	92,900	788,100
Warrant liabilities - related party	2,151,892	2,834,547
Convertible debt - related party	832,100	60,197
Current liabilities of discontinued operations		3,441,198
Total current liabilities	5,956,612	8,608,169
Non-current liabilities of discontinued operations		1,708,732
Total liabilities	5,956,612	10,316,901
Commitments and Contingencies (Note 10)
Qualigen Therapeutics, Inc. stockholders’ equity (deficit):
Common stock, $0.001 par value; 225,000,000 shares authorized; 5,052,463 and 4,210,737 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	42,952	42,110
Additional paid-in capital	112,668,631	110,528,050
Accumulated other comprehensive income		50,721
Accumulated deficit	(114,352,135)	(103,385,172)
Total Qualigen Therapeutics, Inc. stockholders’ equity (deficit)	(1,640,552)	7,235,709
Noncontrolling interest		1,530,881
Total Stockholders’ Equity (deficit)	(1,640,552)	8,766,590
Total Liabilities & Stockholders’ Equity (Deficit)	$ 4,316,060	$ 19,083,491

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	225,000,000	225,000,000
Common stock, shares outstanding	5,052,463	4,210,737
Common stock, shares issued	5,052,463	4,210,737

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
EXPENSES
General and administrative	$ 1,336,765	$ 2,539,389	$ 5,132,834	$ 7,705,823
Research and development	1,441,598	930,536	3,898,061	3,618,428
Total expenses	2,778,363	3,469,925	9,030,895	11,324,251
LOSS FROM OPERATIONS	(2,778,363)	(3,469,925)	(9,030,895)	(11,324,251)
OTHER EXPENSE (INCOME), NET
(Gain) loss on change in fair value of warrant liabilities	101,112	(321,300)	(1,377,855)	(1,019,342)
Interest expense (income), net	367,257	(4,631)	1,288,908	(15,763)
Loss on voluntary conversion of convertible debt			1,077,287
Loss on fixed asset disposal	21,747		21,747
Other income, net	(33,454)		(33,534)
Total other expense (income), net	456,662	(325,931)	976,553	(1,035,105)
LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES	(3,235,025)	(3,143,994)	(10,007,448)	(10,289,146)
(BENEFIT) PROVISION FOR INCOME TAXES				6,173
NET LOSS FROM CONTINUING OPERATIONS	(3,235,025)	(3,143,994)	(10,007,448)	(10,295,319)
DISCONTINUED OPERATIONS
Income (loss) from discontinued operations	159,507	(911,882)	(683,008)	(2,207,864)
Loss on disposal of discontinued operations	(619,545)		(619,545)
LOSS FROM DISCONTINUED OPERATIONS	(460,038)	(911,882)	(1,302,553)	(2,207,864)
Net loss	(3,695,063)	(4,055,876)	(11,310,001)	(12,503,183)
Net loss attributable to non-controlling interest from discontinued operations	(38,526)	(230,767)	(343,038)	(234,883)
Net loss attributable to Qualigen Therapeutics, Inc.	$ (3,656,537)	$ (3,825,109)	$ (10,966,963)	$ (12,268,300)
Net loss per common share, basic - continuing operations	$ (0.64)	$ (0.80)	$ (1.99)	$ (2.77)
Net loss per common share, diluted - continuing operations	(0.64)	(0.80)	(1.99)	(2.77)
Net loss per common share, basic - discontinued operations	(0.08)	(0.17)	(0.19)	(0.53)
Net loss per common share, diluted - discontinued operations	$ (0.08)	$ (0.17)	$ (0.19)	$ (0.53)
Weighted-average number of shares outstanding, basic	5,052,463	3,944,406	5,021,691	3,715,462
Weighted-average number of shares outstanding, diluted	5,052,463	3,944,406	5,021,691	3,715,462
Other comprehensive loss, net of tax
Foreign currency translation adjustment from discontinued operations		$ 88,523	$ (50,721)	$ 154,063
Other comprehensive loss	(3,695,063)	(3,967,353)	(11,360,722)	(12,349,120)
Comprehensive loss attributable to noncontrolling interest from discontinued operations	(38,526)	(230,767)	(343,038)	(234,883)
Comprehensive loss attributable to Qualigen Therapeutics, Inc.	$ (3,656,537)	$ (3,736,586)	$ (11,017,684)	$ (12,114,237)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2021	$ 35,290	$ 101,274,073		$ (84,744,629)	$ 16,564,734		$ 16,564,734
Balance, shares at Dec. 31, 2021	3,529,018
Stock-based compensation		1,267,166			1,267,166		1,267,166
Net loss				(4,319,787)	(4,319,787)		(4,319,787)
Stock issued upon exercise of warrants	$ 5	4,711			4,716		4,716
Stock issued upon exercise of warrants, shares	536
Balance at Mar. 31, 2022	$ 35,295	102,545,950		(89,064,416)	13,516,829		13,516,829
Balance, shares at Mar. 31, 2022	3,529,554
Balance at Dec. 31, 2021	$ 35,290	101,274,073		(84,744,629)	16,564,734		16,564,734
Balance, shares at Dec. 31, 2021	3,529,018
Net loss							(12,503,183)
Balance at Sep. 30, 2022	$ 42,110	108,967,248	154,063	(97,012,929)	12,150,492	3,765,117	15,915,609
Balance, shares at Sep. 30, 2022	4,211,018
Balance at Mar. 31, 2022	$ 35,295	102,545,950		(89,064,416)	13,516,829		13,516,829
Balance, shares at Mar. 31, 2022	3,529,554
Stock-based compensation		1,423,282			1,423,282		1,423,282
Foreign currency translation adjustment			65,540		65,540		65,540
Net loss				(4,123,404)	(4,123,404)	(4,116)	(4,127,520)
Common stock issued for business acquisition	$ 3,500	1,841,000			1,844,500		1,844,500
Common stock issued for business acquisition, shares	350,000
Prefunded warrants issued for business acquisition		1,746,816			1,746,816		1,746,816
Estimated fair value of noncontrolling interest related to business acquisition						4,000,000	4,000,000
Fair value of warrant modification for business acquisition		696			696		696
Balance at Jun. 30, 2022	$ 38,795	107,557,744	65,540	(93,187,820)	14,474,259	3,995,884	18,470,143
Balance, shares at Jun. 30, 2022	3,879,554
Stock-based compensation		1,409,504			1,409,504		1,409,504
Foreign currency translation adjustment			88,523		88,523		88,523
Net loss				(3,825,109)	(3,825,109)	(230,767)	(4,055,876)
Stock issued upon exercise of warrants	$ 3,315				3,315		3,315
Stock issued upon exercise of warrants, shares	331,464
Balance at Sep. 30, 2022	$ 42,110	108,967,248	154,063	(97,012,929)	12,150,492	3,765,117	15,915,609
Balance, shares at Sep. 30, 2022	4,211,018
Balance at Dec. 31, 2022	$ 42,110	110,528,050	50,721	(103,385,172)	7,235,709	1,530,881	8,766,590
Balance, shares at Dec. 31, 2022	4,210,737
Voluntary conversion of convertible debt into common stock	$ 842	1,111,740			1,112,582		1,112,582
Voluntary conversion of convertible debt into common stock, shares	841,726
Stock-based compensation		247,657			247,657	4,569	252,226
Foreign currency translation adjustment			119,723		119,723	56,497	176,220
Net loss				(3,846,221)	(3,846,221)	(261,028)	(4,107,249)
Balance at Mar. 31, 2023	$ 42,952	111,887,447	170,444	(107,231,393)	4,869,450	1,330,919	6,200,369
Balance, shares at Mar. 31, 2023	5,052,463
Balance at Dec. 31, 2022	$ 42,110	110,528,050	50,721	(103,385,172)	7,235,709	1,530,881	8,766,590
Balance, shares at Dec. 31, 2022	4,210,737
Net loss							(11,310,001)
Balance at Sep. 30, 2023	$ 42,952	112,668,631		(114,352,135)	(1,640,552)		(1,640,552)
Balance, shares at Sep. 30, 2023	5,052,463
Balance at Mar. 31, 2023	$ 42,952	111,887,447	170,444	(107,231,393)	4,869,450	1,330,919	6,200,369
Balance, shares at Mar. 31, 2023	5,052,463
Stock-based compensation		667,383			667,383	4,728	672,111
Foreign currency translation adjustment			(38,553)		(38,553)	(18,194)	(56,747)
Net loss				(3,464,205)	(3,464,205)	(43,484)	(3,507,689)
Balance at Jun. 30, 2023	$ 42,952	112,554,830	131,891	(110,695,598)	2,034,075	1,273,969	3,308,044
Balance, shares at Jun. 30, 2023	5,052,463
Stock-based compensation		113,801			113,801		113,801
Net loss				(3,656,537)	(3,656,537)	(38,526)	(3,695,063)
Deconsolidation of discontinued operations			(131,891)		(131,891)	(1,235,443)	(1,367,334)
Balance at Sep. 30, 2023	$ 42,952	$ 112,668,631		$ (114,352,135)	$ (1,640,552)		$ (1,640,552)
Balance, shares at Sep. 30, 2023	5,052,463

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (11,310,001)	$ (12,503,183)
Loss from discontinued operations, net of tax	(1,302,553)	(2,207,864)
Loss from continuing operations	(10,007,448)	(10,295,319)
Adjustments to reconcile loss from continuing operations to net cash used in operating activities:
Depreciation and amortization		9,122
Stock-based compensation	1,028,841	4,099,952
Change in fair value of warrant liabilities	(1,377,855)	(1,019,342)
Loss on voluntary conversion of convertible debt	1,077,287
Accretion of discount on convertible debt	1,247,198
Loss on disposal of fixed assets	21,747
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(640,105)	(378,498)
Accounts payable	952,269	(291,166)
Accrued expenses and other current liabilities	443,330	(728,233)
Net cash used in operating activities - continuing operations	(7,254,736)	(8,603,484)
Net cash provided by (used in) operating activities - discontinued operations	2,622,059	(2,406,331)
Net cash used in operating activities	(4,632,677)	(11,009,815)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash provided by investing activities - discontinued operations	3,980,541	60,612
Net cash provided by investing activities	3,980,541	60,612
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from warrant exercises		7,173
Payments on convertible notes payable	(440,000)
Net cash (used in)/provided by financing activities- continuing operations	(440,000)	7,173
Net cash used in financing activities - discontinued operations
Net cash (used in)/provided by financing activities	(440,000)	7,173
Net change in cash and restricted cash	(1,092,136)	(10,942,030)
Effect of exchange rate changes on cash and restricted cash		27,523
Cash and restricted cash - beginning of period	3,165,985	17,538,272
Cash and restricted cash - end of period	2,073,849	6,623,765
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest
Taxes	4,900	3,501
NONCASH FINANCING AND INVESTING ACTIVITIES:
Net transfers to equipment held for lease from inventory	83,271
Fair value of warrant liabilities on date of exercise		858
Voluntary conversion of convertible debt into common stock	$ 1,112,582

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES	NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES Organization Ritter Pharmaceuticals, Inc. (our predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May 22, 2020, upon completing a “reverse recapitalization” transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was renamed Qualigen Therapeutics, Inc. (“Qualigen” or the “Company”). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc. was a wholly-owned subsidiary of the Company. On July 20, 2023, we sold all of the issued and outstanding shares of common stock of Qualigen, Inc. to Chembio Diagnostics, Inc. (“Chembio”), a wholly-owned subsidiary of Biosynex, S.A. (“Biosynex”). Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio (see Note 5 – Discontinued Operations). On May 26, 2022, the Company acquired 2,232,861 350,000 331,464 0.001 These warrants were subsequently exercised on September 13, 2022 381,786 600,000 52.8 Basis of Presentation The accompanying condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), Regulation S-X and rules and regulations of the Securities and Exchange Commission (“SEC”). Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its former wholly-owned and majority owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional currency of the Company and its subsidiaries is the U.S. dollar. For NanoSynex, the functional currency was the local currency, New Israeli Shekels (NIS). As such, assets and liabilities for NanoSynex were translated into U.S. dollars with the effects of foreign currency translation adjustments reflected as a component of accumulated other comprehensive income within the Company’s consolidated statements of changes in stockholders’ equity. As of July 20, 2023, NanoSynex was deconsolidated from these financial statements as the transactions contemplated by the NanoSynex Amendment resulted in a loss of control of a subsidiary that constitutes a business under ASC 810. The retained investment in NanoSynex is accounted for prospectively as an equity method investment. See Note 5 – Discontinued Operations for further information. Discontinued Operations On July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. The sale of Qualigen Inc. constituted a significant disposition and as such, the Company concluded that the disposition of ownership in Qualigen, Inc. represented a strategic shift that had a major effect on its operations and financial results. Therefore, Qualigen, Inc. is classified as discontinued operations for all periods presented herein. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (“NanoSynex”) (the “NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a former majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex. The disposition represents a strategic shift that will have a material effect on the Company’s operations and financial results. Accordingly, the business of NanoSynex is classified as discontinued operations for all periods presented herein. See Note 5 - Discontinued Operations for further information. Equity Method Investments Following deconsolidation of NanoSynex on July 20, 2023, the Company accounts for its retained investment under the equity method of accounting as it retained the ability to exercise significant influence over the operating and financial policies of the investee. Under the equity method, the Company recognizes its proportionate share earnings or losses each reporting period with an adjustment to the carrying value of the investment. As of September 30, 2023, the carrying value of the retained investment was zero, and therefore the Company has suspended application of the equity method as the Company is not liable for the obligations of the investee nor otherwise committed to provide financial support. Future equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses in prior periods. See Note 5 – Discontinued Operations for further information. Accounting Estimates Management uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant liabilities, and stock-based compensation. Actual results could vary from the estimates that were used. Reverse Stock Split On November 23, 2022, the Company effected a 1-for-10, reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduced the Company’s shares of outstanding common stock, stock options, and warrants to purchase shares of common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged. Cash The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents. The Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S. that are of high quality. Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations. In March 2023, Silicon Valley Bank and Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity concerns and taken over by the Federal Deposit Insurance Corporation (FDIC). While the Company did not have an account at any of these banks, in the event of failure of any of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. Impairment of Long-Lived Assets The Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between the net book value of the assets and their estimated fair values. During the three and nine months ended September 30, 2023 and 2022, no Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and managed its business as one segment operating primarily within the United States (and in Israel prior to the NanoSynex deconsolidation). Research and Development Except for acquired in process research and development (IPR&D), the Company expenses research and development costs as incurred including therapeutics license costs. Patent Costs The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the condensed consolidated statement of operations. Business Combinations The Company accounts for business combinations using the acquisition method pursuant to Financial Accounting Standards Board’s (“FASB”) ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company’s financial results beginning on the respective acquisition date, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of the intangible asset. Any excess of the fair value of consideration transferred (the “purchase price”) over the fair values of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred. Derivative Financial Instruments and Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the condensed consolidated statements of operations and other comprehensive income (loss). Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 7 - Warrant Liabilities and Note 8 - Convertible Debt-Related Party). Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows: ● Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date; ● Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and ● Level 3 - Inputs that are unobservable. Fair Value of Financial Instruments Cash, accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Comprehensive Loss Comprehensive loss consists of net income and foreign currency translation adjustments related to the discontinued operations of NanoSynex. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate component in the statements of stockholders’ equity for all periods presented. Stock-Based Compensation Stock-based compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in an increase to stock-based compensation expense to employees and non-employees determined at the date of grant. Income Taxes Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years. Foreign Currency Translation The functional currency for the Company is the U.S. dollar. The functional currency for the discontinued operations of NanoSynex was the New Israeli Shekel (NIS). The financial statements of NanoSynex were translated into U.S. dollars using exchange rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations; and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of NanoSynex was reflected as a separate component of other comprehensive income (loss) (see Note 5 - Discontinued Operations). Ongoing Wars in Ukraine and Israel In February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the conflict on the Company’s business and financial results remains uncertain and will depend on the severity and duration of the conflict and its impact on regional and global economic conditions. In October 2023, Hamas conducted several terrorist attacks in Israel resulting in ongoing war across the country. In addition, there continue to be hostilities between Israel and Hezbollah in Lebanon and Hamas in the Gaza Strip, both of which resulted in rockets being fired into Israel, causing casualties and disruption of economic activities. In early 2023, there were a number of changes proposed to the political system in Israel by the current government which, if implemented as planned, could lead to large-scale protests and additional uncertainty, negatively impacting the operating environment in Israel. Popular uprisings in various countries in the Middle East over the last few years have also affected the political stability of those countries and have led to a decline in the regional security situation. Such instability may also lead to deterioration in the political and trade relationships that exist between Israel and these countries. Any armed conflicts, terrorist activities or political instability involving Israel or other countries in the region could adversely affect our minority interest in NanoSynex, its results of operations, financial condition, cash flows and prospects (see Note 5 - Discontinued Operations). Inflation and Global Economic Conditions During the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary pressures attributable to ongoing economic recovery and supply chain issues. The Company is subject to inflationary pressures with respect to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its suppliers to mitigate the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with suppliers include negotiation of cost-reductions and identification of more cost competitive suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that it will be successful in fully offsetting increased costs resulting from inflationary pressure. In addition, the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global recession in the near future. If the global economy slows, our business would be adversely affected. Impact of COVID-19 Pandemic The COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company’s business as well. During the height of the pandemic, sales of diagnostic products decreased significantly and the Company’s net loss increased significantly, clinics and small hospitals’ demand for Qualigen, Inc.’s FastPack™ diagnostic test kits reduced sharply, largely due to deferral of patients’ non-emergency visits to physician offices. In July 2023 we sold Qualigen, Inc., our wholly-owned subsidiary, to Chembio (see Note 5 - Discontinued Operations). Other accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company’s condensed consolidated financial statements.

LIQUIDITY

LIQUIDITY	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY	NOTE 2 — LIQUIDITY As of September 30, 2023, we had approximately $ 2.1 114.4 4.6 11.0 On July 20, 2023, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Chembio Diagnostics, Inc. (“Chembio”), Biosynex, S.A. (“Biosynex”) and Qualigen, Inc., a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued and outstanding shares of common stock (collectively, the “Shares”) of Qualigen, Inc., which was the legal entity operating the Company’s FastPack™ diagnostics business (the “Transaction”). The Transaction closed on July 20, 2023. Following the consummation of the Transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio. The aggregate net purchase price paid to the Company for the Shares was $ 5.2 5.8 5.2 450,000 235,000 The Company’s cash balances as of the date that these financial statements were issued along with the proceeds from the above sale to Chembio, without additional financing, are expected to fund operations into the first quarter of 2024. The Company expects to continue to have net losses and negative cash flow from operations, which over time will challenge its liquidity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued. There is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order to fully execute its business plan, the Company will require significant additional financing for planned research and development activities, capital expenditures, clinical testing for its QN-302 clinical trials and preclinical development of RAS, as well as commercialization activities. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from the issuance of debt. In December 2021, the Company raised $ 8.8 3.0 On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (“NanoSynex”) (the “NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a former majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex. However, the Company intends to forfeit shares in lieu of additional funding (see Note 5 - Discontinued Operations). To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of its common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises additional funds through government or other third-party funding, commercialization, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company. Additional funding may not be available to the Company on acceptable terms, or at all. In addition, any future financing (depending on the terms and conditions) may be subject to the approval of Alpha Capital, the holder of the Debenture, or trigger certain adjustments to the Debenture and/or warrants held by Alpha Capital. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ from those reflected in the accompanying financial statements

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	9 Months Ended
	Sep. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 3 — PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following at September 30, 2023 and December 31, 2022: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS September 30, December 31, 2023 2022 Prepaid insurance $ 740,770 $ 1,329,033 Other prepaid expenses 53,787 37,671 Receivable from sale of Qualigen, Inc. 235,402 — Prepaid research and development expenses 345,771 — Prepaid expenses and other current assets $ 1,375,730 $ 1,366,704 Prepaid expenses attributable to Qualigen, Inc. and NanoSynex were disposed of as discontinued operations (see Note 5 - Discontinued Operations).

OTHER NON-CURRENT ASSETS

OTHER NON-CURRENT ASSETS	9 Months Ended
	Sep. 30, 2023
Investments, All Other Investments [Abstract]
OTHER NON-CURRENT ASSETS	NOTE 4 — OTHER NON-CURRENT ASSETS Other non-current assets consisted of the following at September 30, 2023: SCHEDULE OF OTHER NON CURRENT ASSETS September 30, 2023 Funds held in escrow $ 450,000 Long-term research and development deposits 416,481 Other non-current assets $ 866,481

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	9 Months Ended
	Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	NOTE 5 — DISCONTINUED OPERATIONS Sale of Qualigen Inc. On July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. for cash consideration of $ 5.5 4.7 450,000 235,402 The assets and liabilities classified in discontinued operations for Qualigen, Inc. as of December 31, 2022 are as follows ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS December 31, 2022 Cash $ 2,246,482 Accounts receivable, net 512,088 Inventory, net 1,586,297 Prepaid expenses and other current assets 104,132 Total current assets of discontinued operations 4,448,999 Right-of-use assets 1,422,538 Property and equipment, net 289,696 Intangible assets, net 145,702 Other assets 18,334 Total non-current assets of discontinued operations 1,876,270 Total assets of discontinued operations of Qualigen, Inc. $ 6,325,269 Accounts payable $ 236,470 Accrued vacation 187,906 Accrued expenses and other current liabilities 518,766 Deferred revenue, current portion 116,161 Operating lease liability, current portion 240,645 Total current liabilities of discontinued operations 1,299,948 Operating lease liability, net of current portion 1,301,919 Deferred revenue, net of current portion 49,056 Total non-current liabilities of discontinued operations 1,350,975 Total liabilities of discontinued operations of Qualigen, Inc. $ 2,650,923 The Company reclassified the following operations to discontinued operations for the three and nine months ended September 30, 2023 and 2022, respectively: 2023 2022 2023 2022 For the Three Months Ended September 30, For the Nine Months Ended September 30, 2023 2022 2023 2022 REVENUES Net product sales $ 426,920 $ 1,441,065 $ 3,661,121 $ 3,593,628 Total revenues 426,920 1,441,065 3,661,121 3,593,628 EXPENSES Cost of product sales 269,747 1,278,029 2,551,114 3,206,553 General and administrative 26,346 78,632 610,559 471,804 Research and development 2,612 268,127 206,819 942,484 Sales and marketing 37,288 239,865 405,626 683,291 Total expenses 335,993 1,864,653 3,774,118 5,304,132 OTHER EXPENSE (INCOME), NET Loss on disposal of equipment held for lease — — 63,302 — Other expense (income), net 149 (1,139 ) (4,898 ) (795 ) Loss on fixed asset disposal — — 300 — Total other expense (income), net 149 (1,139 ) 58,704 (795 ) INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL 90,778 (422,449 ) (171,701 ) (1,709,709 ) Gain on sale of Qualigen, Inc. 3,859,465 — 3,859,465 — INCOME (LOSS) FROM DISCONTINUED OPERATIONS OF QUALIGEN, INC. $ 3,950,243 $ (422,449 ) $ 3,687,764 $ (1,709,709 ) In connection with this transaction, the Company recorded a gain on the sale of Qualigen, Inc. in its condensed consolidated financial statements for the three and nine months ended September 30, 2023: Gain on sale of Qualigen, Inc. Fair value of consideration received $ 5,489,337 Working capital adjustment 235,402 Total Assets of discontinued operations (4,225,562 ) Total Liabilities of discontinued operations 3,005,407 Transaction expenses (645,119 ) Gain on sale of Qualigen, Inc. $ 3,859,465 Amendment and Settlement Agreement with NanoSynex Ltd. On July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the NanoSynex Funding Agreement with NanoSynex (the “NanoSynex Funding Agreement”), pursuant to which the Company agreed to, among other things, forfeit 281,000 52.8 49.7 3.0 52.8 49.97 The NanoSynex Amendment supersedes any payment obligations contemplated by the original NanoSynex Funding Agreement and amended the Company’s obligations to provide funding to NanoSynex, except that Company agreed to provide future funding as follows: (i) $ 560,000 670,000 i.e 1.5716 The surrender of Series B Preferred Shares of NanoSynex was accounted for as a loss of control of a subsidiary that constitutes a business under ASC 810. As a result, on July 20, 2023, the Company deconsolidated NanoSynex’s related assets, liabilities, accumulated other comprehensive income, and the noncontrolling interest. Subsequently, the retained investment in NanoSynex is accounted for as an equity method investment. On the date of deconsolidation, the Company recognized its retained investment at fair value, which during the preparation of these financial statements was determined to be de minimis based on various economic, industry, and other factors. As a result, the Company has discontinued recognition of its proportionate share of equity method losses following the date of initial recognition. Future equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses in prior periods. Based upon the magnitude of the disposition and because the Company is exiting certain research and development operations, the disposition represents a strategic shift that will have a material effect on the Company’s operations and financial results. Accordingly, the business of NanoSynex is classified as discontinued operations for all periods presented herein. The assets and liabilities classified in discontinued operations for NanoSynex as of December 31, 2022 are as follows: ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS December 31, 2022 Cash $ 1,621,967 Accounts receivable, net 26,499 Prepaid expenses and other current assets 190,384 Total current assets of discontinued operations 1,838,850 Restricted cash 5,690 Property and equipment, net 29,149 Intangible assets, net 5,700,000 Goodwill 625,602 Total non-current assets of discontinued operations 6,360,441 Total assets of discontinued operations of NanoSynex $ 8,199,291 Accounts payable $ 1,273 Accrued vacation 115,002 Accrued expenses and other current liabilities 293,571 R&D grant liability 780,682 Short term debt-related party 950,722 Total current liabilities of discontinued operations 2,141,250 Deferred tax liability 357,757 Total non-current liabilities of discontinued operations 357,757 Total liabilities of discontinued operations of NanoSynex $ 2,499,007 The Company reclassified the following operations to discontinued operations for the three and nine months ended September 30, 2023 and 2022, respectively: 2023 2022 2023 2022 For the Three Months Ended For the Nine Months Ended 2023 2022 2023 2022 EXPENSES Research and development $ 81,640 $ 489,433 $ 869,064 $ 498,155 Total expenses 81,640 489,433 869,064 498,155 Loss on disposal of discontinued operations 4,479,010 — 4,479,010 — (BENEFIT) PROVISION FOR INCOME TAXES (150,369 ) — (357,757 ) — LOSS FROM DISCONTINUED OPERATIONS (4,410,281 ) (489,433 ) (4,990,317 ) (498,155 ) Loss attributable to noncontrolling interest (1,276,969 ) (230,767 ) (1,578,481 ) (234,883 ) NET LOSS ATTRIBUTABLE TO STOCKHOLDERS $ (3,133,312 ) $ (258,666 ) $ (3,411,836 ) $ (263,272 ) In connection with this transaction, the Company recorded a loss on deconsolidation of NanoSynex in its condensed consolidated financial statements for the three and nine months ended September 30, 2023: Loss on deconsolidation of NanoSynex Fair value of NanoSynex interest retained $ — Net assets deconsolidated (2,768,403 ) Non-controlling interest share 1,235,443 Accumulated OCI attributable to NanoSynex 131,891 Forgiveness of debt (3,077,941 ) Loss from deconsolidation of NanoSynex $ (4,479,010 )

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 6 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following at September 30, 2023 and December 31, 2022: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES September 30, December 31, 2023 2022 Board compensation $ 40,833 70,000 Interest (Convertible debt - related party) 68,322 2,829 License fees 167,200 150,130 Payroll 35,939 1,247 Professional fees 506,080 136,203 Research and development 278,024 329,412 Other 47,790 9,698 Accrued expenses and other current liabilities $ 1,144,188 $ 699,519 Other accrued liabilities attributable to Qualigen Inc, and NanoSynex were disposed of as discontinued operations (see Note 5 - Discontinued Operations).

WARRANT LIABILITIES

WARRANT LIABILITIES	9 Months Ended
	Sep. 30, 2023
Warrant Liabilities
WARRANT LIABILITIES	NOTE 7 – WARRANT LIABILITIES In 2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a private placement (the “Series C Warrants”). The Series C Warrants were subsequently extended and, upon closing of the reverse recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, at $ 7.195 0.14 0.74 7.195 6.00 49,318 6.00 5.136 49,952 247,625 346,896 5.136 1,002,717 Additionally, on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha Capital (see Note 8 – Convertible Debt – Related Party), the Company issued to Alpha Capital a warrant to purchase 2,500,000 1.65 125 The following table summarizes the activity in liability classified warrants for the nine months ended September 30, 2023: SCHEDULE OF WARRANTS ACTIVITY Common Stock Warrants Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2022 3,849,571 $ 1.53 $ 1.32 1.65 3.9 Exercised — — — — Forfeited — — — — Expired — — — — Granted — — — — Total outstanding – September 30, 2023 3,849,571 $ 1.53 $ 1.32 1.65 3.16 Exercisable 3,849,571 $ 1.53 $ 1.32 1.65 3.16 The following table summarizes the activity in liability classified warrants for the nine months ended September 30, 2022: Common Stock Warrants Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding –December 31, 2021 248,161 $ 7.20 2.00 Exercised (536 ) 7.20 Forfeited (247,625 ) 7.20 Expired — — Granted 346,896 5.10 Total outstanding – September 30, 2022 346,896 $ 5.10 Exercisable 346,896 $ 5.10 $ 5.10 1.26 The following table presents the Company’s fair value hierarchy for its liabilities measured at fair value on a recurring basis as of September 30, 2023: SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES Quoted Market Significant Prices for Other Significant Identical Observable Unobservable Assets Inputs Inputs Common Stock Warrant liabilities (Level 1) (Level 2) (Level 3) Total Balance as of December 31, 2022 $ — $ — $ 3,622,647 $ 3,622,647 Exercises — — — — Gain on change in fair value of warrant liabilities — — (1,377,855 ) (1,377,855 ) Balance as of September 30, 2023 $ — $ — $ 2,244,792 $ 2,244,792 There were no transfers of financial assets or liabilities between category levels for the three and nine months ended September 30, 2023. The value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher or lower fair value measurements. The following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of September 30, 2023 and 2022: SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES September 30, 2023 September 30, 2022 Range Weighted Range Weighted Risk-free interest rate 4.523 5.401 % 4.83 % 3.99 4.09 % 4.01 % Expected volatility (peer group) 57.9 134.5 % 108.41 % 91 93 % 92.0 % Term of warrants (in years) .14 4.73 3.16 1.14 1.74 1.26 Expected dividend yield 0.00 % 0.00 % 0.00 % 0.00 %

CONVERTIBLE DEBT - RELATED PART

CONVERTIBLE DEBT - RELATED PARTY	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
CONVERTIBLE DEBT - RELATED PARTY	NOTE 8 — CONVERTIBLE DEBT - RELATED PARTY On December 22, 2022, the Company issued to Alpha Capital an 8% 3,300,000 3,000,000 December 22, 2025 1.32 2,500,000 1.65 125% The proceeds from the transaction were used to advance the Company’s QN-302 Investigative New Drug candidate towards clinical trials and other working capital purposes. Commencing June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption of the Debenture (each such date, a “Monthly Redemption Date”), the Company must redeem $ 110,000 105% The Debenture accrues interest at the rate of 8% Both the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and exercise price, respectively, in connection with stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions. Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha Capital upon 61 days’ notice to the Company. The Company filed a resale registration statement on Form S-3 (File Number 333-269088) on December 30, 2022 registering the resale by Alpha Capital of up to 5,157,087 3,958,537 The Company evaluated the Debenture and the Alpha Warrant and determined that the Alpha Warrant is a freestanding financial instrument. The Alpha Warrant is not considered indexed to the Company’s own stock, because the settlement amount would not equal the difference between the fair value of a fixed number of the Company’s equity shares and a fixed strike price and all of the adjustment features in Section 3(b) of the Alpha Warrant are not down round provisions, as defined in ASU 2017-11. Accordingly, the Alpha Warrant is classified as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings. The proceeds from the Debenture were allocated to the initial fair value of the Alpha Warrant, with the residual balance allocated to the initial carrying value of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized as proceeds received after allocating the proceeds to the Alpha Warrant, and then allocating remaining proceeds to a suite of bifurcated embedded derivative features (conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event of Default), with the resulting difference, if any, allocated to the loan host instrument. The suite of derivative features was measured and determined to have no fair value. The original issue discount of $ 0.3 2.8 0 0.1 Between January 9 and 12, 2023, the Company issued 841,726 1.32 1,111,078 1.1 On September 22, 2023, the Company entered into a consent and waiver (the “Waiver”) with Alpha Capital. Pursuant to the Waiver, Alpha Capital consented to the Company’s election to pay all of the Monthly Redemption Amount for October 2023 in Conversion Shares (the “October Payment”) and waived the requirement of satisfaction of the Equity Conditions in relation to the October Payment only. On October 3, 2023 the Company issued 128,595 During the three and nine months ended September 30, 2023, the Company recorded interest of approximately $ 368,000 1.3 350,000 1.2 2.2 0 Convertible debt-related party is comprised of the following as of September 30, 2023 and December 31, 2022: SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT September 30, 2023 December 31, 2022 Senior secured convertible debenture $ 1,748,922 $ 3,300,000 Discount on convertible debenture (916,822 ) (3,239,803 ) Total convertible debt-related party $ 832,100 $ 60,197 As of September 30, 2023, there were no events of default or violation of any covenants under our financing obligations, except for the Equity Conditions in relation to the Company’s ability to elect to pay all of the Monthly Redemption Amount for October 2023 in Conversion Shares as described above.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	NOTE 9 — EARNINGS (LOSS) PER SHARE Basic loss per share (“EPS”) is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from stock options and warrants. The following potentially dilutive securities have been excluded from diluted net loss per share as of September 30, 2023 and 2022 because their effect would be anti-dilutive: SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE As of September 30, 2023 2022 Shares of common stock subject to outstanding options 416,215 607,175 Shares of common stock subject to outstanding warrants 4,059,934 1,080,873 Total common stock equivalents 4,476,149 1,688,048

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 — COMMITMENTS AND CONTINGENCIES NanoSynex Funding Commitment On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (“NanoSynex”) (the “NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex. However, the Company intends to forfeit shares in lieu of additional funding (see Note 5 - Discontinued Operations). Litigation and Other Legal Proceedings On November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (“Mediant”) in the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $ 96,558

RESEARCH AND LICENSE AGREEMENTS

RESEARCH AND LICENSE AGREEMENTS	9 Months Ended
	Sep. 30, 2023
Research And License Agreements
RESEARCH AND LICENSE AGREEMENTS	NOTE 11 — RESEARCH AND LICENSE AGREEMENTS The University of Louisville Research Foundation In March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company agreed to reimburse ULRF for sponsored research expenses of initially up to $ 693,000 2.9 In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020 50,000 5,000,000 50,000 100,000 150,000 300,000 5,000,000 500,000,000 20,000 100,000 Sponsored research expenses related to these agreements for the three months ended September 30, 2023 and 2022 were approximately $ 101,000 and $ 196,000 , respectively, and for the nine months ended September 30, 2023 and 2022 were approximately $ 657,000 and $ 601,000 , respectively, and are recorded in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss. License costs related to these agreements for the three months ended September 30, 2023 and 2022 were approximately $ 18,000 and $ 27,000 , respectively, and for the nine months ended September 30, 2023 and 2022 were approximately $ 47,000 and $ 44,000 , respectively, and are included in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss. Between June 2018 and April 2022, the Company entered into license and sponsored research agreements with the University of Louisville Research Foundation (“ULRF”) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. Under the agreements, the Company took over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $ 50,000 805,000 200,000 In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $ 100,000 5,000,000 100,000 200,000 350,000 500,000 5,000,000 500,000,000 500,000 10,000 50,000 The sponsored research agreement for QN-247 expired in August 2022 and there were no sponsored research expenses for the three months ended September 30, 2023 and 2022. For the nine months ended September 30, 2023 and 2022 were $ 0 and approximately $164,000 in sponsored research expenses related to these agreements , respectively, and these amounts are recorded in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss. License costs were $ 0 and approximately $ 5,000 related to these agreements for the three months ended September 30, 2023 and 2022, respectively, and approximately $ 22,000 and $ 74,000 related to these agreements for the nine months ended September 30, 2023 and 2022, respectively, and are included in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss. In June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the compound (for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $ 24,000 250,000 430,000 There were no sponsored research expenses or license costs related to these agreements for the three months ended September 30, 2023 and 2022, or for the nine months ended September 30, 2023 and 2022. UCL Business Limited In January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for University College London.) The program’s lead compound is now being developed at Qualigen under the name QN-302 as a candidate for treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. The License Agreement required a $ 150,000 160,000 For the three months ended September 30, 2023 and 2022, there were license costs of $ 12,000 0 28,000 310,000 QN-302 Phase 1 Study In June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC (“TD2”) whereby TD2 agreed to perform certain clinical research and development services for the Company including but not limited to trial management, side identification and selection, site monitoring/management, medical monitoring, project management, data collection, statistical programming or analysis, quality assurance auditing, scientific and medical communications, regulatory affairs consulting and submissions, strategic consulting, and/or other related services. From time to time, the Company shall enter into statements of work with TD2 for the performance of specific services under this Master Clinical Research Services Agreement. In June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (“MLM”) whereby MLM agreed to perform certain clinical research and development services for the Company including but not limited to laboratory, supply, testing, validation, data management, and storage services. From time to time, the Company shall enter into work orders with MLM for the performance of specific services under this Master Laboratory Services Agreement. In June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc. (“Clinigen”) whereby Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the Company shall enter into statements of work with Clinigen for the performance of specific services under this Master Services Agreement. In July 2023, pursuant to the above agreements, the Company entered into work orders and statements of work for clinical trial services for the conduct of the QN-302 Phase 1 study. The project timeline started in July 2023 and is expected to continue until approximately July 2026. The total amount to be paid under these work orders and statements of work is currently expected to be approximately $ 7.6

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT)	NOTE 12 — STOCKHOLDERS’ EQUITY (DEFICIT) As of September 30, 2023 and December 31, 2022, the Company had two classes of authorized capital stock: common stock and preferred stock. Common Stock Holders of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions. On December 22, 2022, the Company issued to Alpha Capital an 8% 3,300,000 3,000,000 December 22, 2025 1.32 2,500,000 1,111,078 841,726 1.32 At September 30, 2023, the Company reserved 4,476,149 SCHEDULE OF RESERVED SHARES Exercise of issued and future grants of stock options 416,215 Exercise of stock warrants 4,059,934 Total 4,476,149 Preferred Stock At September 30, 2023 and December 31, 2022, there were no shares of preferred stock outstanding. Stock Options and Warrants Stock Options The Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting period. In April 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which provides for the granting of incentive or non-statutory common stock options and other types of awards to qualified employees, officers, directors, consultants and other service providers. At September 30, 2023 and December 31, 2022, there were 416,215 608,012 339,487 147,690 The following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers that are outstanding at September 30, 2023, and changes during the nine-month period then ended: SCHEDULE OF STOCK OPTION ACTIVITY Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2022 608,012 $ 35.02 $ 5.14 51.30 8.09 Granted — — — — Expired — — — — Forfeited (191,797 ) 34.02 5.14 51.30 — Total outstanding – September 30, 2023 416,215 $ 35.50 $ 5.14 51.30 7.31 Exercisable (vested) 330,544 $ 42.38 $ 5.14 51.30 7.01 Non-Exercisable (non-vested) 85,671 $ 8.97 $ 5.14 35.20 8.52 There was approximately $ 1.0 4.0 0.4 1.31 Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 484,186 $ 60.70 $ 12.40 14,657.50 8.52 Granted 132,975 5.10 5.10 10.50 9.77 Expired (9,386 ) 935.90 57.50 14,657.50 — Forfeited (600 ) 35.50 12.40 49.70 — Total outstanding – September 30, 2022 607,175 $ 35.10 $ 10.50 51.30 8.33 Exercisable (vested) 266,016 $ 48.40 $ 12.40 51.30 7.76 Non-Exercisable (non-vested) 341,159 $ 36.80 $ 10.50 51.30 8.82 The exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a ten-year period. Fair Value of Equity Awards The Company utilizes the Black-Scholes option pricing model to value awards under its equity plans. Key valuation assumptions include: ● Expected dividend yield. ● Expected stock-price volatility. ● Risk-free interest rate. ● Expected term. The material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows: SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD For the Nine Months Ended September 30, 2023 2022 Expected dividend yield 0.00 % 0.00 % Expected stock-price volatility — 103 Risk-free interest rate — 1.58% 3.03 % Expected average term of options (in years) — 6.00 Stock price $ — $ 0.52 The Company recorded share-based compensation expense and classified it in the condensed consolidated statements of operations as follows: SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE 2023 2022 For the Nine Months Ended September 30, 2023 2022 General and administrative $ 881,365 $ 3,522,108 Research and development 140,674 577,844 Total $ 1,022,039 $ 4,099,952 Equity Classified Compensatory Warrants In connection with the $ 4.0 81,143 11.10 In addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier for the purchase of 66,802 23.40 During the year ended December 31, 2021, the Company issued equity classified compensatory warrants to a service provider for the purchase of 60,000 13.20 0.3 60,000 13.20 6.00 June 3, 2023 to September 14, 2023, when they expired 67,370 67,619 11.10 5.136 31,010 67,620 5.136 1.32 8,548 No compensatory warrants were issued during the nine months ended September 30, 2023. The following table summarizes the activity in the common stock equity classified compensatory warrants for the nine months ended September 30, 2023: SCHEDULE OF WARRANT ACTIVITY Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2022 179,046 $ 9.12 $ 1.32 25.40 1.73 Granted to advisor and its designees — — Exercised — — Expired (60,000 ) 6.00 6.00 Forfeited — — Total outstanding – September 30, 2023 119,046 $ 10.69 $ 1.32 25.40 1.50 Exercisable 119,046 $ 10.69 $ 1.32 25.40 1.50 Non-Exercisable — $ — $ — — The following table summarizes the activity in the common stock equity classified compensatory warrants for the nine months ended September 30, 2022: Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 179,065 $ 15.20 $ 11.10 25.40 2.64 Granted to advisor and its designees — — Exercised — — Expired — — Forfeited — — Total outstanding – September 30, 2022 179,065 $ 10.60 $ 5.14 25.40 1.98 Exercisable 179,065 $ 10.60 $ 5.14 25.40 1.98 Non-Exercisable — $ — $ — — There were no 67,370 Noncompensatory Equity Classified Warrants In May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to Alpha Capital (a related party) for the purchase of 27,048 11.10 20,000 78,019 0.01 192,068 52.50 128,783 60.00 100,000 0.10 219,101 40.70 331,464 0.01 On November 29, 2021, with the exception of the warrants to purchase 27,048 11.10 539,951 20.00 2.3 331,464 0.01 In conjunction with the NanoSynex Acquisition, on April 25, 2022 the exercise price of 7,048 11.10 6.00 2,533 5.136 696 1.32 891 No noncompensatory equity classified warrants were issued during the nine months ended September 30, 2023. The following table summarizes the noncompensatory equity classified warrant activity for the nine months ended September 30, 2023: SCHEDULE OF WARRANT ACTIVITY Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2022 547,003 $ 19.76 $ 1.32 20.00 0.33 Legacy Ritter warrants — — Granted — — Exercised — — Expired (455,685 ) 20.00 20.00 Forfeited — — Total outstanding – September 30, 2023 91,318 $ 18.56 Exercisable 91,318 $ 18.56 $ 1.32 20.00 0.33 Non-Exercisable — $ — $ — — The following table summarizes the noncompensatory equity classified warrant activity for the nine months ended September 30, 2022: Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 554,914 $ 20.10 Legacy Ritter warrants — — Granted 331,464 0.01 0.01 Exercised (331,464 ) 0.01 0.01 Expired — — Forfeited — — Total outstanding – September 30, 2022 554,914 $ 20.10 Exercisable 554,914 $ 20.10 $ 5.10 37.70 0.57 Non-Exercisable — $ — $ — —

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 13 — RELATED PARTY TRANSACTIONS Convertible Debt See Note 8 – Convertible Debt – Related Party for additional information concerning convertible debt - related party transactions. On December 22, 2022, the Company issued to Alpha Capital, an 8% 3,300,000 3,000,000 1.32 Warrant Liabilities Additionally, on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha Capital, the Company issued to Alpha Capital a warrant to purchase 2,500,000 1.65 125

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 — SUBSEQUENT EVENTS In October 2023, Hamas conducted several terrorist attacks in Israel resulting in ongoing war across the country. In addition, there continue to be hostilities between Israel and Hezbollah in Lebanon and Hamas in the Gaza Strip, both of which resulted in rockets being fired into Israel, causing casualties and disruption of economic activities. In early 2023, there were a number of changes proposed to the political system in Israel by the current government which, if implemented as planned, could lead to large-scale protests and additional uncertainty, negatively impacting the operating environment in Israel. Popular uprisings in various countries in the Middle East over the last few years have also affected the political stability of those countries and have led to a decline in the regional security situation. Such instability may also lead to deterioration in the political and trade relationships that exist between Israel and these countries. Any armed conflicts, terrorist activities or political instability involving Israel or other countries in the region could adversely affect our minority interest in NanoSynex, its results of operations, financial condition, cash flows and prospects (see Note 5 - Discontinued Operations). On October 3, 2023 the Company issued 128,595 On November 7, 2023 the Company announced that first patient dosing occurred for its QN-302 Phase 1a clinical trial which triggered a $ 100,000

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), Regulation S-X and rules and regulations of the Securities and Exchange Commission (“SEC”).
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its former wholly-owned and majority owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional currency of the Company and its subsidiaries is the U.S. dollar. For NanoSynex, the functional currency was the local currency, New Israeli Shekels (NIS). As such, assets and liabilities for NanoSynex were translated into U.S. dollars with the effects of foreign currency translation adjustments reflected as a component of accumulated other comprehensive income within the Company’s consolidated statements of changes in stockholders’ equity. As of July 20, 2023, NanoSynex was deconsolidated from these financial statements as the transactions contemplated by the NanoSynex Amendment resulted in a loss of control of a subsidiary that constitutes a business under ASC 810. The retained investment in NanoSynex is accounted for prospectively as an equity method investment. See Note 5 – Discontinued Operations for further information.
Discontinued Operations	Discontinued Operations On July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. The sale of Qualigen Inc. constituted a significant disposition and as such, the Company concluded that the disposition of ownership in Qualigen, Inc. represented a strategic shift that had a major effect on its operations and financial results. Therefore, Qualigen, Inc. is classified as discontinued operations for all periods presented herein. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (“NanoSynex”) (the “NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a former majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex. The disposition represents a strategic shift that will have a material effect on the Company’s operations and financial results. Accordingly, the business of NanoSynex is classified as discontinued operations for all periods presented herein. See Note 5 - Discontinued Operations for further information.
Equity Method Investments	Equity Method Investments Following deconsolidation of NanoSynex on July 20, 2023, the Company accounts for its retained investment under the equity method of accounting as it retained the ability to exercise significant influence over the operating and financial policies of the investee. Under the equity method, the Company recognizes its proportionate share earnings or losses each reporting period with an adjustment to the carrying value of the investment. As of September 30, 2023, the carrying value of the retained investment was zero, and therefore the Company has suspended application of the equity method as the Company is not liable for the obligations of the investee nor otherwise committed to provide financial support. Future equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses in prior periods. See Note 5 – Discontinued Operations for further information.
Accounting Estimates	Accounting Estimates Management uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant liabilities, and stock-based compensation. Actual results could vary from the estimates that were used.
Reverse Stock Split	Reverse Stock Split On November 23, 2022, the Company effected a 1-for-10, reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduced the Company’s shares of outstanding common stock, stock options, and warrants to purchase shares of common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.
Cash	Cash The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents. The Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S. that are of high quality. Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations. In March 2023, Silicon Valley Bank and Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity concerns and taken over by the Federal Deposit Insurance Corporation (FDIC). While the Company did not have an account at any of these banks, in the event of failure of any of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between the net book value of the assets and their estimated fair values. During the three and nine months ended September 30, 2023 and 2022, no
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and managed its business as one segment operating primarily within the United States (and in Israel prior to the NanoSynex deconsolidation).
Research and Development	Research and Development Except for acquired in process research and development (IPR&D), the Company expenses research and development costs as incurred including therapeutics license costs.
Patent Costs	Patent Costs The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the condensed consolidated statement of operations.
Business Combinations	Business Combinations The Company accounts for business combinations using the acquisition method pursuant to Financial Accounting Standards Board’s (“FASB”) ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company’s financial results beginning on the respective acquisition date, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of the intangible asset. Any excess of the fair value of consideration transferred (the “purchase price”) over the fair values of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.
Derivative Financial Instruments and Warrant Liabilities	Derivative Financial Instruments and Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the condensed consolidated statements of operations and other comprehensive income (loss). Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 7 - Warrant Liabilities and Note 8 - Convertible Debt-Related Party). Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows: ● Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date; ● Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and ● Level 3 - Inputs that are unobservable.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Cash, accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
Comprehensive Loss	Comprehensive Loss Comprehensive loss consists of net income and foreign currency translation adjustments related to the discontinued operations of NanoSynex. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate component in the statements of stockholders’ equity for all periods presented.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.
Income Taxes	Income Taxes Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years.
Foreign Currency Translation	Foreign Currency Translation The functional currency for the Company is the U.S. dollar. The functional currency for the discontinued operations of NanoSynex was the New Israeli Shekel (NIS). The financial statements of NanoSynex were translated into U.S. dollars using exchange rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations; and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of NanoSynex was reflected as a separate component of other comprehensive income (loss) (see Note 5 - Discontinued Operations).
Ongoing Wars in Ukraine and Israel	Ongoing Wars in Ukraine and Israel In February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the conflict on the Company’s business and financial results remains uncertain and will depend on the severity and duration of the conflict and its impact on regional and global economic conditions. In October 2023, Hamas conducted several terrorist attacks in Israel resulting in ongoing war across the country. In addition, there continue to be hostilities between Israel and Hezbollah in Lebanon and Hamas in the Gaza Strip, both of which resulted in rockets being fired into Israel, causing casualties and disruption of economic activities. In early 2023, there were a number of changes proposed to the political system in Israel by the current government which, if implemented as planned, could lead to large-scale protests and additional uncertainty, negatively impacting the operating environment in Israel. Popular uprisings in various countries in the Middle East over the last few years have also affected the political stability of those countries and have led to a decline in the regional security situation. Such instability may also lead to deterioration in the political and trade relationships that exist between Israel and these countries. Any armed conflicts, terrorist activities or political instability involving Israel or other countries in the region could adversely affect our minority interest in NanoSynex, its results of operations, financial condition, cash flows and prospects (see Note 5 - Discontinued Operations).
Inflation and Global Economic Conditions	Inflation and Global Economic Conditions During the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary pressures attributable to ongoing economic recovery and supply chain issues. The Company is subject to inflationary pressures with respect to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its suppliers to mitigate the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with suppliers include negotiation of cost-reductions and identification of more cost competitive suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that it will be successful in fully offsetting increased costs resulting from inflationary pressure. In addition, the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global recession in the near future. If the global economy slows, our business would be adversely affected.
Impact of COVID-19 Pandemic	Impact of COVID-19 Pandemic The COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company’s business as well. During the height of the pandemic, sales of diagnostic products decreased significantly and the Company’s net loss increased significantly, clinics and small hospitals’ demand for Qualigen, Inc.’s FastPack™ diagnostic test kits reduced sharply, largely due to deferral of patients’ non-emergency visits to physician offices. In July 2023 we sold Qualigen, Inc., our wholly-owned subsidiary, to Chembio (see Note 5 - Discontinued Operations). Other accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company’s condensed consolidated financial statements.

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	9 Months Ended
	Sep. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	Prepaid expenses and other current assets consisted of the following at September 30, 2023 and December 31, 2022: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS September 30, December 31, 2023 2022 Prepaid insurance $ 740,770 $ 1,329,033 Other prepaid expenses 53,787 37,671 Receivable from sale of Qualigen, Inc. 235,402 — Prepaid research and development expenses 345,771 — Prepaid expenses and other current assets $ 1,375,730 $ 1,366,704

OTHER NON-CURRENT ASSETS (Table

OTHER NON-CURRENT ASSETS (Tables)	9 Months Ended
	Sep. 30, 2023
Investments, All Other Investments [Abstract]
SCHEDULE OF OTHER NON CURRENT ASSETS	Other non-current assets consisted of the following at September 30, 2023: SCHEDULE OF OTHER NON CURRENT ASSETS September 30, 2023 Funds held in escrow $ 450,000 Long-term research and development deposits 416,481 Other non-current assets $ 866,481

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	9 Months Ended
	Sep. 30, 2023
Nano Synex [Member]
ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS	The assets and liabilities classified in discontinued operations for NanoSynex as of December 31, 2022 are as follows: ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS December 31, 2022 Cash $ 1,621,967 Accounts receivable, net 26,499 Prepaid expenses and other current assets 190,384 Total current assets of discontinued operations 1,838,850 Restricted cash 5,690 Property and equipment, net 29,149 Intangible assets, net 5,700,000 Goodwill 625,602 Total non-current assets of discontinued operations 6,360,441 Total assets of discontinued operations of NanoSynex $ 8,199,291 Accounts payable $ 1,273 Accrued vacation 115,002 Accrued expenses and other current liabilities 293,571 R&D grant liability 780,682 Short term debt-related party 950,722 Total current liabilities of discontinued operations 2,141,250 Deferred tax liability 357,757 Total non-current liabilities of discontinued operations 357,757 Total liabilities of discontinued operations of NanoSynex $ 2,499,007 The Company reclassified the following operations to discontinued operations for the three and nine months ended September 30, 2023 and 2022, respectively: 2023 2022 2023 2022 For the Three Months Ended For the Nine Months Ended 2023 2022 2023 2022 EXPENSES Research and development $ 81,640 $ 489,433 $ 869,064 $ 498,155 Total expenses 81,640 489,433 869,064 498,155 Loss on disposal of discontinued operations 4,479,010 — 4,479,010 — (BENEFIT) PROVISION FOR INCOME TAXES (150,369 ) — (357,757 ) — LOSS FROM DISCONTINUED OPERATIONS (4,410,281 ) (489,433 ) (4,990,317 ) (498,155 ) Loss attributable to noncontrolling interest (1,276,969 ) (230,767 ) (1,578,481 ) (234,883 ) NET LOSS ATTRIBUTABLE TO STOCKHOLDERS $ (3,133,312 ) $ (258,666 ) $ (3,411,836 ) $ (263,272 ) In connection with this transaction, the Company recorded a loss on deconsolidation of NanoSynex in its condensed consolidated financial statements for the three and nine months ended September 30, 2023: Loss on deconsolidation of NanoSynex Fair value of NanoSynex interest retained $ — Net assets deconsolidated (2,768,403 ) Non-controlling interest share 1,235,443 Accumulated OCI attributable to NanoSynex 131,891 Forgiveness of debt (3,077,941 ) Loss from deconsolidation of NanoSynex $ (4,479,010 )
Parent [Member]
ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS	The assets and liabilities classified in discontinued operations for Qualigen, Inc. as of December 31, 2022 are as follows ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS December 31, 2022 Cash $ 2,246,482 Accounts receivable, net 512,088 Inventory, net 1,586,297 Prepaid expenses and other current assets 104,132 Total current assets of discontinued operations 4,448,999 Right-of-use assets 1,422,538 Property and equipment, net 289,696 Intangible assets, net 145,702 Other assets 18,334 Total non-current assets of discontinued operations 1,876,270 Total assets of discontinued operations of Qualigen, Inc. $ 6,325,269 Accounts payable $ 236,470 Accrued vacation 187,906 Accrued expenses and other current liabilities 518,766 Deferred revenue, current portion 116,161 Operating lease liability, current portion 240,645 Total current liabilities of discontinued operations 1,299,948 Operating lease liability, net of current portion 1,301,919 Deferred revenue, net of current portion 49,056 Total non-current liabilities of discontinued operations 1,350,975 Total liabilities of discontinued operations of Qualigen, Inc. $ 2,650,923 The Company reclassified the following operations to discontinued operations for the three and nine months ended September 30, 2023 and 2022, respectively: 2023 2022 2023 2022 For the Three Months Ended September 30, For the Nine Months Ended September 30, 2023 2022 2023 2022 REVENUES Net product sales $ 426,920 $ 1,441,065 $ 3,661,121 $ 3,593,628 Total revenues 426,920 1,441,065 3,661,121 3,593,628 EXPENSES Cost of product sales 269,747 1,278,029 2,551,114 3,206,553 General and administrative 26,346 78,632 610,559 471,804 Research and development 2,612 268,127 206,819 942,484 Sales and marketing 37,288 239,865 405,626 683,291 Total expenses 335,993 1,864,653 3,774,118 5,304,132 OTHER EXPENSE (INCOME), NET Loss on disposal of equipment held for lease — — 63,302 — Other expense (income), net 149 (1,139 ) (4,898 ) (795 ) Loss on fixed asset disposal — — 300 — Total other expense (income), net 149 (1,139 ) 58,704 (795 ) INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL 90,778 (422,449 ) (171,701 ) (1,709,709 ) Gain on sale of Qualigen, Inc. 3,859,465 — 3,859,465 — INCOME (LOSS) FROM DISCONTINUED OPERATIONS OF QUALIGEN, INC. $ 3,950,243 $ (422,449 ) $ 3,687,764 $ (1,709,709 ) In connection with this transaction, the Company recorded a gain on the sale of Qualigen, Inc. in its condensed consolidated financial statements for the three and nine months ended September 30, 2023: Gain on sale of Qualigen, Inc. Fair value of consideration received $ 5,489,337 Working capital adjustment 235,402 Total Assets of discontinued operations (4,225,562 ) Total Liabilities of discontinued operations 3,005,407 Transaction expenses (645,119 ) Gain on sale of Qualigen, Inc. $ 3,859,465

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	Accrued expenses and other current liabilities consisted of the following at September 30, 2023 and December 31, 2022: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES September 30, December 31, 2023 2022 Board compensation $ 40,833 70,000 Interest (Convertible debt - related party) 68,322 2,829 License fees 167,200 150,130 Payroll 35,939 1,247 Professional fees 506,080 136,203 Research and development 278,024 329,412 Other 47,790 9,698 Accrued expenses and other current liabilities $ 1,144,188 $ 699,519

WARRANT LIABILITIES (Tables)

WARRANT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2023
Warrant Liabilities
SCHEDULE OF WARRANTS ACTIVITY	The following table summarizes the activity in liability classified warrants for the nine months ended September 30, 2023: SCHEDULE OF WARRANTS ACTIVITY Common Stock Warrants Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2022 3,849,571 $ 1.53 $ 1.32 1.65 3.9 Exercised — — — — Forfeited — — — — Expired — — — — Granted — — — — Total outstanding – September 30, 2023 3,849,571 $ 1.53 $ 1.32 1.65 3.16 Exercisable 3,849,571 $ 1.53 $ 1.32 1.65 3.16 The following table summarizes the activity in liability classified warrants for the nine months ended September 30, 2022: Common Stock Warrants Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding –December 31, 2021 248,161 $ 7.20 2.00 Exercised (536 ) 7.20 Forfeited (247,625 ) 7.20 Expired — — Granted 346,896 5.10 Total outstanding – September 30, 2022 346,896 $ 5.10 Exercisable 346,896 $ 5.10 $ 5.10 1.26
SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES	The following table presents the Company’s fair value hierarchy for its liabilities measured at fair value on a recurring basis as of September 30, 2023: SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES Quoted Market Significant Prices for Other Significant Identical Observable Unobservable Assets Inputs Inputs Common Stock Warrant liabilities (Level 1) (Level 2) (Level 3) Total Balance as of December 31, 2022 $ — $ — $ 3,622,647 $ 3,622,647 Exercises — — — — Gain on change in fair value of warrant liabilities — — (1,377,855 ) (1,377,855 ) Balance as of September 30, 2023 $ — $ — $ 2,244,792 $ 2,244,792
SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES	The following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of September 30, 2023 and 2022: SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES September 30, 2023 September 30, 2022 Range Weighted Range Weighted Risk-free interest rate 4.523 5.401 % 4.83 % 3.99 4.09 % 4.01 % Expected volatility (peer group) 57.9 134.5 % 108.41 % 91 93 % 92.0 % Term of warrants (in years) .14 4.73 3.16 1.14 1.74 1.26 Expected dividend yield 0.00 % 0.00 % 0.00 % 0.00 %

CONVERTIBLE DEBT - RELATED PA_2

CONVERTIBLE DEBT - RELATED PARTY (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT	Convertible debt-related party is comprised of the following as of September 30, 2023 and December 31, 2022: SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT September 30, 2023 December 31, 2022 Senior secured convertible debenture $ 1,748,922 $ 3,300,000 Discount on convertible debenture (916,822 ) (3,239,803 ) Total convertible debt-related party $ 832,100 $ 60,197

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE	The following potentially dilutive securities have been excluded from diluted net loss per share as of September 30, 2023 and 2022 because their effect would be anti-dilutive: SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE As of September 30, 2023 2022 Shares of common stock subject to outstanding options 416,215 607,175 Shares of common stock subject to outstanding warrants 4,059,934 1,080,873 Total common stock equivalents 4,476,149 1,688,048

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)	9 Months Ended
	Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
SCHEDULE OF RESERVED SHARES	SCHEDULE OF RESERVED SHARES Exercise of issued and future grants of stock options 416,215 Exercise of stock warrants 4,059,934 Total 4,476,149
SCHEDULE OF STOCK OPTION ACTIVITY	The following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers that are outstanding at September 30, 2023, and changes during the nine-month period then ended: SCHEDULE OF STOCK OPTION ACTIVITY Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2022 608,012 $ 35.02 $ 5.14 51.30 8.09 Granted — — — — Expired — — — — Forfeited (191,797 ) 34.02 5.14 51.30 — Total outstanding – September 30, 2023 416,215 $ 35.50 $ 5.14 51.30 7.31 Exercisable (vested) 330,544 $ 42.38 $ 5.14 51.30 7.01 Non-Exercisable (non-vested) 85,671 $ 8.97 $ 5.14 35.20 8.52 Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 484,186 $ 60.70 $ 12.40 14,657.50 8.52 Granted 132,975 5.10 5.10 10.50 9.77 Expired (9,386 ) 935.90 57.50 14,657.50 — Forfeited (600 ) 35.50 12.40 49.70 — Total outstanding – September 30, 2022 607,175 $ 35.10 $ 10.50 51.30 8.33 Exercisable (vested) 266,016 $ 48.40 $ 12.40 51.30 7.76 Non-Exercisable (non-vested) 341,159 $ 36.80 $ 10.50 51.30 8.82
SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD	The material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows: SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD For the Nine Months Ended September 30, 2023 2022 Expected dividend yield 0.00 % 0.00 % Expected stock-price volatility — 103 Risk-free interest rate — 1.58% 3.03 % Expected average term of options (in years) — 6.00 Stock price $ — $ 0.52
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE	The Company recorded share-based compensation expense and classified it in the condensed consolidated statements of operations as follows: SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE 2023 2022 For the Nine Months Ended September 30, 2023 2022 General and administrative $ 881,365 $ 3,522,108 Research and development 140,674 577,844 Total $ 1,022,039 $ 4,099,952
Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes the activity in the common stock equity classified compensatory warrants for the nine months ended September 30, 2023: SCHEDULE OF WARRANT ACTIVITY Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2022 179,046 $ 9.12 $ 1.32 25.40 1.73 Granted to advisor and its designees — — Exercised — — Expired (60,000 ) 6.00 6.00 Forfeited — — Total outstanding – September 30, 2023 119,046 $ 10.69 $ 1.32 25.40 1.50 Exercisable 119,046 $ 10.69 $ 1.32 25.40 1.50 Non-Exercisable — $ — $ — — The following table summarizes the activity in the common stock equity classified compensatory warrants for the nine months ended September 30, 2022: Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 179,065 $ 15.20 $ 11.10 25.40 2.64 Granted to advisor and its designees — — Exercised — — Expired — — Forfeited — — Total outstanding – September 30, 2022 179,065 $ 10.60 $ 5.14 25.40 1.98 Exercisable 179,065 $ 10.60 $ 5.14 25.40 1.98 Non-Exercisable — $ — $ — —
Non Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes the noncompensatory equity classified warrant activity for the nine months ended September 30, 2023: SCHEDULE OF WARRANT ACTIVITY Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2022 547,003 $ 19.76 $ 1.32 20.00 0.33 Legacy Ritter warrants — — Granted — — Exercised — — Expired (455,685 ) 20.00 20.00 Forfeited — — Total outstanding – September 30, 2023 91,318 $ 18.56 Exercisable 91,318 $ 18.56 $ 1.32 20.00 0.33 Non-Exercisable — $ — $ — — The following table summarizes the noncompensatory equity classified warrant activity for the nine months ended September 30, 2022: Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 554,914 $ 20.10 Legacy Ritter warrants — — Granted 331,464 0.01 0.01 Exercised (331,464 ) 0.01 0.01 Expired — — Forfeited — — Total outstanding – September 30, 2022 554,914 $ 20.10 Exercisable 554,914 $ 20.10 $ 5.10 37.70 0.57 Non-Exercisable — $ — $ — —

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative) - USD ($)		3 Months Ended			9 Months Ended
	May 26, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Warrants to purchase common stock								219,101
Warrants exercise price							$ 13.20	$ 40.70
Reverse stock split	These warrants were subsequently exercised on September 13, 2022
Stock issued during period, value, acquisitions				$ 1,844,500
Impairment losses on construction-in-progress		$ 0	$ 0		$ 0	$ 0
Pre-funded Warrant [Member]
Warrants to purchase common stock	331,464
Warrants exercise price	$ 0.001
Series B Preferred Stock [Member]
Stock issued during period shares acquisitions	381,786
NanoSynex Ltd [Member]
Stock issued during period shares acquisitions	350,000
Voting interests acquired	52.80%
NanoSynex Ltd [Member] | Series A-1 Preferred Stock [Member]
Stock issued during period shares acquisitions	2,232,861
NanoSynex Ltd [Member] | Series B Preferred Stock [Member]
Stock issued during period, value, acquisitions	$ 600,000

LIQUIDITY (Details Narrative)

LIQUIDITY (Details Narrative) - USD ($)		1 Months Ended	9 Months Ended
	Jul. 20, 2023	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash	$ 5,200,000		$ 2,073,849		$ 3,165,985
Accumulated deficit			114,352,135		103,385,172
Net cash used in operating activities			4,632,677	$ 11,009,815
Share based compensation	5,800,000		1,028,841	$ 4,099,952
Escrow deposit	$ 450,000		450,000
Prepaid expenses and other current assets			235,402
Proceeds from issuance of common stock		$ 8,800,000
Proceeds from issuance of debt		$ 3,000,000
Prepaid Expenses and Other Current Assets [Member]
Prepaid expenses and other current assets			$ 235,000

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 740,770	$ 1,329,033
Other prepaid expenses	53,787	37,671
Receivable from sale of Qualigen, Inc.	235,402
Prepaid research and development expenses	345,771
Prepaid expenses and other current assets	$ 1,375,730	$ 1,366,704

SCHEDULE OF OTHER NON CURRENT A

SCHEDULE OF OTHER NON CURRENT ASSETS (Details) - USD ($)	Sep. 30, 2023	Jul. 20, 2023
Investments, All Other Investments [Abstract]
Funds held in escrow	$ 450,000	$ 450,000
Long-term research and development deposits	416,481
Other non-current assets	$ 866,481

ASSETS AND LIABILITIES CLASSIFI

ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Total current assets of discontinued operations					$ 6,287,849
Total non-current assets of discontinued operations					8,236,711
Total assets of discontinued operations of NanoSynex	(4,225,562)		(4,225,562)
Total current liabilities of discontinued operations					3,441,198
Total non-current liabilities of discontinued operations					1,708,732
Total liabilities of discontinued operations of NanoSynex	3,005,407		3,005,407
INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL	159,507	$ (911,882)	(683,008)	$ (2,207,864)
Fair value of consideration received	5,489,337		5,489,337
Working capital adjustment	235,402		235,402
Transaction expenses	(645,119)		(645,119)
Gain on sale of Qualigen, Inc.	3,859,465		3,859,465
(BENEFIT) PROVISION FOR INCOME TAXES	619,545		619,545
LOSS FROM DISCONTINUED OPERATIONS	(460,038)	(911,882)	(1,302,553)	(2,207,864)
Loss attributable to noncontrolling interest	(38,526)	(230,767)	(343,038)	(234,883)
Nano Synex [Member]
Cash					1,621,967
Accounts receivable, net					26,499
Prepaid expenses and other current assets					190,384
Total current assets of discontinued operations					1,838,850
Property and equipment, net					29,149
Intangible assets, net					5,700,000
Total non-current assets of discontinued operations					6,360,441
Total assets of discontinued operations of NanoSynex					8,199,291
Accounts payable					1,273
Accrued expenses and other current liabilities					293,571
Total current liabilities of discontinued operations					2,141,250
Total non-current liabilities of discontinued operations					357,757
Deferred tax liability					357,757
Total liabilities of discontinued operations of NanoSynex					2,499,007
Research and development	81,640	489,433	869,064	498,155
Total expenses	81,640	489,433	869,064	498,155
NET LOSS ATTRIBUTABLE TO STOCKHOLDERS	(3,133,312)	(258,666)	(3,411,836)	(263,272)
Restricted cash					5,690
Goodwill					625,602
Accrued vacation					115,002
R&D grant liability					780,682
Short term debt-related party					950,722
Loss on disposal of discontinued operations	4,479,010		4,479,010
(BENEFIT) PROVISION FOR INCOME TAXES	(150,369)		(357,757)
LOSS FROM DISCONTINUED OPERATIONS	(4,410,281)	(489,433)	(4,990,317)	(498,155)
Loss attributable to noncontrolling interest	(1,276,969)	(230,767)	(1,578,481)	(234,883)
Fair value of Nan-Synex interest retained
Net assets deconsolidated	(2,768,403)		(2,768,403)
Non-controlling interest share	1,235,443		1,235,443
Accumulated OCI attributable to NanoSynex	131,891		131,891
Forgiveness of debt	(3,077,941)		(3,077,941)
Loss from deconsolidation of NanoSynex	(4,479,010)		(4,479,010)
Parent [Member]
Cash					2,246,482
Accounts receivable, net					512,088
Inventory, net					1,586,297
Prepaid expenses and other current assets					104,132
Total current assets of discontinued operations					4,448,999
Right-of-use assets					1,422,538
Property and equipment, net					289,696
Intangible assets, net					145,702
Other assets					18,334
Total non-current assets of discontinued operations					1,876,270
Total assets of discontinued operations of NanoSynex					6,325,269
Accounts payable					236,470
Accrued vacation					187,906
Accrued expenses and other current liabilities					518,766
Deferred revenue, current portion					116,161
Operating lease liability, current portion					240,645
Total current liabilities of discontinued operations					1,299,948
Total non-current liabilities of discontinued operations					1,301,919
Deferred tax liability					49,056
Total non-current liabilities of discontinued operations					1,350,975
Total liabilities of discontinued operations of NanoSynex					$ 2,650,923
Net product sales	426,920	1,441,065	3,661,121	3,593,628
Total revenues	426,920	1,441,065	3,661,121	3,593,628
Cost of product sales	269,747	1,278,029	2,551,114	3,206,553
General and administrative	26,346	78,632	610,559	471,804
Research and development	2,612	268,127	206,819	942,484
Sales and marketing	37,288	239,865	405,626	683,291
Total expenses	335,993	1,864,653	3,774,118	5,304,132
Loss on disposal of equipment held for lease			63,302
Other expense (income), net	149	(1,139)	(4,898)	(795)
Loss on fixed asset disposal			300
Total other expense (income), net	149	(1,139)	58,704	(795)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL	90,778	(422,449)	(171,701)	(1,709,709)
Gain on sale of Qualigen, Inc.	3,859,465		3,859,465
NET LOSS ATTRIBUTABLE TO STOCKHOLDERS	$ 3,950,243	$ (422,449)	$ 3,687,764	$ (1,709,709)

DISCONTINUED OPERATIONS (Detail

DISCONTINUED OPERATIONS (Details Narrative) - USD ($)	Jul. 20, 2023	Mar. 31, 2024	Nov. 30, 2023	Sep. 30, 2023	Jan. 12, 2023	Dec. 31, 2022
Cash	$ 5,200,000			$ 2,073,849		$ 3,165,985
Purchase Price	4,700,000
Escrow deposit	$ 450,000			450,000
Escrow deposit				$ 235,402
Aggregrate amount					$ 1,111,078
Nano Synex [Member] | Maximum [Member]
Business Acquisition, Percentage of Voting Interests Acquired	52.80%
Nano Synex [Member] | Minimum [Member]
Business Acquisition, Percentage of Voting Interests Acquired	49.97%
Series B Preferred Stock [Member] | Nano Synex [Member] | Maximum [Member]
Business Acquisition, Percentage of Voting Interests Acquired	52.80%
Series B Preferred Stock [Member] | Nano Synex [Member] | Minimum [Member]
Business Acquisition, Percentage of Voting Interests Acquired	49.70%
Preferred A-1 Stock [Member]
Sale of stock price per share	$ 1.5716
Amendment and Settlement Agreement [Member]
Aggregrate amount	$ 3,000,000
Amendment and Settlement Agreement [Member] | Series B Preferred Stock [Member]
Aggregrate amount	281,000
Chembio Diagnostics [Member]
Cash	$ 5,500,000
NanoSynex Ltd [Member] | Amendment and Settlement Agreement [Member] | Forecast [Member]
Aggregrate amount		$ 670,000	$ 560,000

SCHEDULE OF ACCRUED EXPENSES AN

SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Board compensation	$ 40,833	$ 70,000
Interest (Convertible debt - related party)	68,322	2,829
License fees	167,200	150,130
Payroll	35,939	1,247
Professional fees	506,080	136,203
Research and development	278,024	329,412
Other	47,790	9,698
Accrued expenses and other current liabilities	$ 1,144,188	$ 699,519

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - Series C Warrants [Member] - Common Stock Warrants [Member] - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Number of Shares, Warrants Outstanding Beginning	3,849,571	248,161
Weighted Average Exercise Price Per Share Warrants Outstanding Beginning	$ 1.53	$ 7.20
Weighted Average Remaining Contractual Term	3 years 10 months 24 days	2 years
Number of Shares, Warrants Exercised		(536)
Weighted Average Exercise Price Per Share Warrants Exercised		$ 7.20
Number of Shares, Warrants Forfeited		(247,625)
Weighted Average Exercise Price Per Share Warrants Forfeited		$ 7.20
Number of Shares, Warrants Expired
Weighted Average Exercise Price Per Share Warrants Expired
Number of Shares, Warrants Granted		346,896
Weighted Average Exercise Price Per Share Warrants Granted		$ 5.10
Number of Shares, Warrants Outstanding Ending	3,849,571	346,896
Weighted Average Exercise Price Per Share Warrants Outstanding Ending	$ 1.53	$ 5.10
Weighted Averag Remaining Contractual Term	3 years 1 month 28 days
Number of Shares, Warrants Exercisable	3,849,571	346,896
Range of Exercise Price, Exercisable		$ 5.10
Exercisable Weighted Averag Remaining Contractual Term	3 years 1 month 28 days	1 year 3 months 3 days
Weighted Average Exercise Price Per Share Exercisable		$ 5.10
Minimum [Member]
Range of Exercise Beginning	$ 1.32
Range of Exercise Ending	1.32
Range of Exercise Price, Exercisable	1.32
Maximum [Member]
Range of Exercise Beginning	1.65
Range of Exercise Ending	1.65
Range of Exercise Price, Exercisable	$ 1.65

SCHEDULE OF FAIR VALUE HIERARCH

SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Platform Operator, Crypto-Asset [Line Items]
Fair value for warrant liabilities, beginning balance	$ 3,622,647
Common Stock Warrant liabilities, Exercises		$ (858)
Change in fair value of warrant liabilities	(1,377,855)
Fair value for warrant liabilities, ending balance	2,244,792
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Fair value for warrant liabilities, beginning balance
Common Stock Warrant liabilities, Exercises
Change in fair value of warrant liabilities
Fair value for warrant liabilities, ending balance
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Fair value for warrant liabilities, beginning balance
Common Stock Warrant liabilities, Exercises
Change in fair value of warrant liabilities
Fair value for warrant liabilities, ending balance
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Fair value for warrant liabilities, beginning balance	3,622,647
Common Stock Warrant liabilities, Exercises
Change in fair value of warrant liabilities	(1,377,855)
Fair value for warrant liabilities, ending balance	$ 2,244,792

SCHEDULE OF ASSUMPTIONS OF WARR

SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)	Sep. 30, 2023	Sep. 30, 2022
Measurement Input, Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentages	0	0
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	4.523	3.99
Minimum [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	57.9	91
Minimum [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	1 month 20 days	1 year 1 month 20 days
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	5.401	4.09
Maximum [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	134.5	93
Maximum [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	4 years 8 months 23 days	1 year 8 months 26 days
Weighted Average [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	4.83	4.01
Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	108.41	92
Weighted Average [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	3 years 1 month 28 days	1 year 3 months 3 days
Weighted Average [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentages	0	0

WARRANT LIABILITIES (Details Na

WARRANT LIABILITIES (Details Narrative) - $ / shares	Dec. 22, 2022	Dec. 22, 2022	May 26, 2022	Apr. 25, 2022	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2021	Dec. 31, 2020
Exercise price of warrant							$ 13.20	$ 40.70
Warrants forfeited			247,625
Warrants reissued			346,896
Warrant to purchase shares							60,000
Minimum [Member] | Series C Warrants [Member]
Exercise price of warrant			$ 5.136	$ 6
Warrants and rights outstanding term					1 month 20 days
Maximum [Member] | Series C Warrants [Member]
Exercise price of warrant	$ 5.136	$ 5.136	$ 6	$ 7.195
Warrants and rights outstanding term					8 months 26 days
Series C Warrants [Member]
Exercise price of warrant						$ 7.195
Warrants issued		1,002,717	49,952	49,318
Series C Warrants [Member] | Alpha Capital [Member]
Exercise price of warrant	$ 1.65	$ 1.65
Warrant to purchase shares	2,500,000	2,500,000
Conversion price percentage	125%	125%

SCHEDULE OF SENIOR SECURED CONV

SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Total convertible debt-related party	$ 832,100	$ 60,197
Senior Secured Convertible Debt [Member]
Short-Term Debt [Line Items]
Senior secured convertible debenture	1,748,922	3,300,000
Discount on convertible debenture	(916,822)	(3,239,803)
Total convertible debt-related party	$ 832,100	$ 60,197

CONVERTIBLE DEBT - RELATED PA_3

CONVERTIBLE DEBT - RELATED PARTY (Details Narrative) - USD ($)							3 Months Ended		9 Months Ended
	Oct. 03, 2023	Sep. 01, 2023	May 26, 2023	Jan. 12, 2023	Dec. 22, 2022	Dec. 22, 2022	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Jul. 20, 2023	Jun. 30, 2023	Dec. 31, 2022	Dec. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Short-Term Debt [Line Items]
Purchase Price											$ 4,700,000
Conversion price				$ 1.32
Warrant to purchase shares															60,000
Exercise price of warrant															$ 13.20	$ 40.70
Debenture accrues interest rate					8%	8%
Shares of Common stock, issued							5,052,463		5,052,463				4,210,737
Debt discount amortization							$ 350,000		$ 1,200,000
Fair value of warrants			$ 696						(1,377,855)	$ (1,019,342)
Shares of common stock				841,726
Debenture voluntarily converted				$ 1,111,078
Debt conversion of convertible debt				$ 1,100,000
Interest amounted							368,000		1,300,000
Fair value of warrants							2,200,000		2,200,000
Derivative fair value of warrants							0		0
Common Stock [Member]
Short-Term Debt [Line Items]
October payment in shares								841,726
October Payment [Member] | Common Stock [Member] | Alpha Capital [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
October payment in shares	128,595
Alpha Capital [Member]
Short-Term Debt [Line Items]
Shares of Common stock, issued														5,157,087
Resale of common stock shares		3,958,537
Series C Warrants [Member]
Short-Term Debt [Line Items]
Exercise price of warrant												$ 7.195
Senior Convertible Debenture [Member]
Short-Term Debt [Line Items]
Redeemable debt						$ 110,000
Principal amount percentage						105%
Alpha Capital [Member] | Series C Warrants [Member]
Short-Term Debt [Line Items]
Warrant to purchase shares					2,500,000	2,500,000
Exercise price of warrant					$ 1.65	$ 1.65
Conversion price percentage					125%	125%
Alpha Capital [Member] | Senior Convertible Debenture [Member]
Short-Term Debt [Line Items]
Senior convertible debenture rate						8%
Principal amount					$ 3,300,000	$ 3,300,000
Purchase Price					$ 3,000,000	$ 3,000,000
Maturity date						Dec. 22, 2025
Conversion price					$ 1.32	$ 1.32
Alpha Capital Other Third Parties [Member]
Short-Term Debt [Line Items]
Debt discount amortization									300,000
Fair value of warrants									2,800,000
Fair value of embedded derivative features							$ 0		0
Fees and costs paid									$ 100,000

SCHEDULE OF DILUTIVE SECURITIES

SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	4,476,149	1,688,048
Shares of Common Stock Subject to Outstanding Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	416,215	607,175
Shares of Common Stock Subject to Outstanding Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	4,059,934	1,080,873

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)	Apr. 05, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Litigation paid	$ 96,558

RESEARCH AND LICENSE AGREEMEN_2

RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($)	1 Months Ended							3 Months Ended		9 Months Ended		47 Months Ended
	Jul. 31, 2023	Jan. 31, 2022	Dec. 31, 2021	Nov. 30, 2020	Jul. 31, 2020	Jun. 30, 2020	Mar. 31, 2019	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Apr. 30, 2022
Research and Development Expense								$ 1,441,598	$ 930,536	$ 3,898,061	$ 3,618,428
Proceeds from convertible debt			$ 3,000,000
Sponsored Research and License Agreement [Member]
Research and Development Expense										0
License cost								0	5,000	22,000	74,000
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member]
Reimbursement of research expenses							$ 693,000			2,900,000
Agreement term payment, description					In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020
Marketing approval expenses					$ 300,000
Revenue					500,000,000							$ 500,000,000
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]
Upfront license fee					20,000
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]
Upfront license fee					100,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]
Reimbursement of research expenses												$ 805,000
Agreement term payment, description												In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.
Marketing approval expenses												$ 500,000
Proceeds from convertible debt												50,000
Patent costs												200,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member]
Cumulative sales					5,000,000							5,000,000
Regulatory marketing approval, expenses												500,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 1 Clinical Trial [Member]
Milestone payment					50,000							100,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 2 Clinical Trial [Member]
Milestone payment					100,000							200,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 3 Clinical Trial [Member]
Milestone payment					150,000							350,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]
Milestone payment					50,000							100,000
Shortfall payments												10,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]
Milestone payment					$ 5,000,000							5,000,000
Shortfall payments												$ 50,000
Sponsored Research Agreements And License [Member]
Research and Development Expense								101,000	196,000	657,000	601,000
License cost								18,000	27,000	47,000	44,000
License Agreement [Member]
License cost								$ 12,000	$ 0	$ 28,000	$ 310,000
Reimbursement of patent		$ 160,000
License Agreement [Member] | Upfront Payment [Member]
Reimbursement of patent		$ 150,000
License Agreement [Member] | University of Louisville Research Foundation [Member]
Upfront license fee						$ 24,000
License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]
Research and Development Expense				$ 430,000		$ 250,000
Master Laboratory Services Agreement [Member] | MLM Medical Labs [Member]
Research and Development Expense	$ 7,600,000

SCHEDULE OF RESERVED SHARES (De

SCHEDULE OF RESERVED SHARES (Details)	Sep. 30, 2023 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	4,476,149
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	416,215
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	4,059,934

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending	1 year 3 months 21 days
Employees and Non-employee Service Provider [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of shares, options outstanding, beginning	608,012	484,186	484,186
Range of Exercise price, Options Outstanding	$ 35.02	$ 60.70	$ 60.70
Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning			8 years 1 month 2 days	8 years 6 months 7 days
Number of shares, options granted		132,975
Weighted average exercise price, options granted		$ 5.10
Number of shares, options expired		(9,386)
Weighted average exercise price, options expired		$ 935.90
Number of shares, options forfeited	(191,797)	(600)
Weighted average exercise price, options forfeited	$ 34.02	$ 35.50
Number of Shares, Options Outstanding at Ending	416,215	607,175	608,012	484,186
Range of Exercise price, Options Outstanding	$ 35.50	$ 35.10	$ 35.02	$ 60.70
Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending	7 years 3 months 21 days	8 years 3 months 29 days
Number of shares, options exercisable (vested)	330,544	266,016
Range of exercise price, options exercisable (vested)	$ 42.38	$ 48.40
Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)	7 years 3 days	7 years 9 months 3 days
Number of shares, options non-exercisable (non-vested)	85,671	341,159
Weighted average exercise price, options non-exercisable (non-vested)	$ 8.97	$ 36.80
Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)	8 years 6 months 7 days	8 years 9 months 25 days
Employees and Non-employee Service Provider [Member] | Minimum [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Range of Exercise price, Options Outstanding	$ 5.14	$ 12.40	12.40
Range of Exercise price, Options Forfeited	5.14	12.40
Range of Exercise price, Options Outstanding	5.14	10.50	5.14	12.40
Range of exercise price, options exercisable (vested)	5.14	12.40
Range of exercise price, options non-exercisable (non-vested)	5.14	10.50
Employees and Non-employee Service Provider [Member] | Maximum [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Range of Exercise price, Options Outstanding	51.30	14,657.50	14,657.50
Range of Exercise price, Options Forfeited	51.30	49.70
Range of Exercise price, Options Outstanding	51.30	51.30	$ 51.30	$ 14,657.50
Range of exercise price, options exercisable (vested)	51.30	51.30
Range of exercise price, options non-exercisable (non-vested)	$ 35.20	$ 51.30

SCHEDULE OF ASSUMPTION USED IN

SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Expected dividend yield	0%	0%
Expected stock-price volatility		103%
Risk-free interest rate, minimum
Expected average term of options (in years)		6 years
Share price		$ 0.52
Minimum [Member]
Risk-free interest rate, minimum		1.58%
Maximum [Member]
Risk-free interest rate, minimum		3.03%

SCHEDULE OF SHARE-BASED COMPENS

SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Total	$ 1,022,039	$ 4,099,952
General and Administrative Expense [Member]
Total	881,365	3,522,108
Research and Development Expense [Member]
Total	$ 140,674	$ 577,844

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Non Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares, Warrants Outstanding Beginning		547,003	547,003	554,914
Weighted Average Exercise Price Per Share Warrants Outstanding Beginning		$ 19.76	$ 19.76	$ 20.10
Weighted average remaining life (Years) exercisable			3 months 29 days
Number of shares, warrants granted		331,464
Weighted average exercise price, warrants granted		$ 0.01
Number of Shares, Warrants Exercised		331,464
Weighted average exercise price, warrants exercised		$ 0.01
Number of Shares, Warrants Expired	(455,685)
Weighted average exercise price, warrants expired	$ 20
Number of Shares, Warrants Forfeited
Weighted average exercise price, warrants forfeited
Number of Shares, Warrants Outstanding Ending	91,318	554,914		547,003
Weighted Average Exercise Price Per Share Warrants Outstanding Ending	$ 18.56	$ 20.10		$ 19.76
Number of Shares, Warrants Exercisable	91,318	554,914
Weighted average exercise price, exercisable	$ 18.56	$ 20.10
Weighted average remaining life (Years) exercisable	3 months 29 days	6 months 25 days
Number of shares legal ritter warrants
Weighted average exercise price, legal ritter warrants
Number of Shares, Warrants Exercised		(331,464)
Range of exercise price, granted	$ 20	$ 0.01
Number of Shares, Warrants Exercisable
Weighted average exercise price, exercisable
Minimum [Member] | Non Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise price		1.32	$ 1.32
Range of exercise price - ending				1.32
Range of exercise price - Exercisable	1.32	5.10
Maximum [Member] | Non Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise price		20	$ 20
Range of exercise price - ending				$ 20
Range of exercise price - Exercisable	$ 20	$ 37.70
Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares, Warrants Outstanding Beginning	179,046	179,065	179,065
Weighted Average Exercise Price Per Share Warrants Outstanding Beginning	$ 9.12	$ 15.20	$ 15.20
Weighted average remaining life (Years) exercisable	1 year 6 months	1 year 11 months 23 days	1 year 8 months 23 days	2 years 7 months 20 days
Number of shares, warrants granted
Weighted average exercise price, warrants granted
Number of Shares, Warrants Exercised
Weighted average exercise price, warrants exercised
Number of Shares, Warrants Expired	(60,000)
Weighted average exercise price, warrants expired	$ 6
Range of exercise price, expired	$ 6
Number of Shares, Warrants Forfeited
Weighted average exercise price, warrants forfeited
Number of Shares, Warrants Outstanding Ending	119,046	179,065	179,046	179,065
Weighted Average Exercise Price Per Share Warrants Outstanding Ending	$ 10.69	$ 10.60	$ 9.12	$ 15.20
Number of Shares, Warrants Exercisable	119,046	179,065
Weighted average exercise price, exercisable	$ 10.69	$ 10.60
Weighted average remaining life (Years) exercisable	1 year 6 months	1 year 11 months 23 days
Number of shares, warrants non-exercisable
Weighted Average Exercise Price Per Share Non-Exercisable
Range of Exercise Price, Non-Exercisable
Number of Shares, Warrants Exercised
Compensatory Warrant Activity [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise price	$ 1.32	$ 11.10	11.10
Range of exercise price - ending	1.32	5.14	1.32	11.10
Range of exercise price - Exercisable	1.32	5.14
Compensatory Warrant Activity [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise price	25.40	25.40	25.40
Range of exercise price - ending	25.40	25.40	$ 25.40	$ 25.40
Range of exercise price - Exercisable	$ 25.40	$ 25.40

STOCKHOLDERS_ EQUITY (DEFICIT_2

STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) - USD ($)						1 Months Ended		9 Months Ended		12 Months Ended
	Jul. 20, 2023	May 26, 2023	Jan. 12, 2023	Dec. 22, 2022	Apr. 25, 2022	May 26, 2022	Dec. 31, 2020	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2023	May 31, 2022	Nov. 29, 2021	Aug. 31, 2020	Jul. 31, 2020	May 31, 2020	Dec. 31, 2017
Class of Stock [Line Items]
Purchase Price	$ 4,700,000
Conversion price			$ 1.32
Purchase of warrants											60,000
Debenture voluntarily converted			$ 1,111,078
Shares of common stock			841,726
Plan shares available								4,476,149
Compensation cost	$ 5,800,000							$ 1,028,841	$ 4,099,952
Unrecognized compensation cost								$ 400,000
Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending								1 year 3 months 21 days
Purchase of warrants							219,101
Class of warrant or right, exercise							$ 40.70				$ 13.20
Fair value of issuance cost											$ 300,000
Fair value adjustment of warrants		$ 696						$ (1,377,855)	(1,019,342)
Compensation cost								1,022,039	4,099,952
Nano Synex [Member]
Class of Stock [Line Items]
Purchase of warrants					7,048
Class of warrant or right, exercise				$ 1.32	$ 11.10	$ 5.136
Fair value adjustment of warrants				$ 891	$ 2,533
Modified to exercise price					$ 6
General and Administrative Expense [Member]
Class of Stock [Line Items]
Compensation cost								881,365	3,522,108
Warrant [Member]
Class of Stock [Line Items]
Purchase of warrants					60,000
Purchase of warrants				67,620	67,619	67,619
Class of warrant or right, exercise					$ 6
Reverse stock split, price per share					$ 13.20
Warrants extended date description					June 3, 2023 to September 14, 2023, when they expired
Fair value adjustment of warrants				$ 8,548
Warrant [Member] | General and Administrative Expense [Member]
Class of Stock [Line Items]
Fair value adjustment of warrants					$ 67,370
Additional Paid-in Capital [Member] | Warrant [Member]
Class of Stock [Line Items]
Fair value adjustment of warrants						$ 31,010
Compensatory Warrant Activity [Member]
Class of Stock [Line Items]
Compensation cost								$ 0	67,370
Minimum [Member] | Warrant [Member]
Class of Stock [Line Items]
Class of warrant or right, exercise				$ 5.136	$ 11.10	$ 11.10
Maximum [Member] | Warrant [Member]
Class of Stock [Line Items]
Class of warrant or right, exercise				$ 1.32	$ 5.136	$ 5.136
Equity Option [Member]
Class of Stock [Line Items]
Plan shares available								416,215
Equity Option [Member] | 2020 Stock Incentive Plan [Member]
Class of Stock [Line Items]
Plan shares available								339,487		147,690
Options outstanding								416,215		608,012
Number of shares, options outstanding, beginning								608,012
Number of Shares, Options Outstanding at Ending								416,215		608,012
Share-Based Compensation Arrangement by Share-Based Payment Award, Description								The exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the date of grant.
Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Compensation cost								$ 1,000,000	$ 4,000,000
Compensatory Warrants [Member]
Class of Stock [Line Items]
Issuance or sale of equity								$ 4,000,000
Purchase of warrants								81,143										66,802
Class of warrant or right, exercise								$ 11.10										$ 23.40
Noncompensatory Equity Classified Warrants [Member]
Class of Stock [Line Items]
Purchase of warrants													331,464	27,048		192,068	27,048
Class of warrant or right, exercise													$ 0.01	$ 20		$ 52.50	$ 11.10
Fair value adjustment of warrants								$ 2,300,000
Warrants exercised							20,000
Number of outstanding warrants to purchase, shares														539,951
Noncompensatory Equity Classified Warrants [Member] | Warrant [Member]
Class of Stock [Line Items]
Class of warrant or right, exercise														$ 11.10
Series C Warrants [Member]
Class of Stock [Line Items]
Class of warrant or right, exercise												$ 7.195
Alpha Capital [Member] | Noncompensatory Equity Classified Warrants [Member]
Class of Stock [Line Items]
Purchase of warrants							100,000									78,019
Class of warrant or right, exercise							$ 0.10									$ 0.01
Alpha Capital [Member] | Noncompensatory Equity Classified Warrants [Member] | Warrant [Member]
Class of Stock [Line Items]
Purchase of warrants															128,783
Class of warrant or right, exercise															$ 60
Alpha Capital [Member] | Series C Warrants [Member]
Class of Stock [Line Items]
Purchase of warrants				2,500,000
Class of warrant or right, exercise				$ 1.65
Alpha Capital [Member] | Senior Convertible Debenture [Member]
Class of Stock [Line Items]
Senior convertible debenture rate				8%
Principal amount				$ 3,300,000
Purchase Price				$ 3,000,000
Maturity date				Dec. 22, 2025
Conversion price				$ 1.32
Employees and Non-employee Service Provider [Member]
Class of Stock [Line Items]
Options outstanding								416,215	607,175	608,012	484,186
Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending								7 years 3 months 21 days	8 years 3 months 29 days
Number of shares, options outstanding, beginning								608,012	484,186	484,186
Range of Exercise price, Options Outstanding								$ 35.02	$ 60.70	$ 60.70
Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning										8 years 1 month 2 days	8 years 6 months 7 days
Number of shares, options granted									132,975
Weighted average exercise price, options granted									$ 5.10
Weighted- Average Remaining Contractual Life (in Years), Options Granted									9 years 9 months 7 days
Number of shares, options expired									(9,386)
Weighted average exercise price, options expired									$ 935.90
Number of shares, options forfeited								(191,797)	(600)
Weighted average exercise price, options forfeited								$ 34.02	$ 35.50
Number of Shares, Options Outstanding at Ending								416,215	607,175	608,012	484,186
Range of Exercise price, Options Outstanding								$ 35.50	$ 35.10	$ 35.02	$ 60.70
Number of shares, options exercisable (vested)								330,544	266,016
Range of exercise price, options exercisable (vested)								$ 42.38	$ 48.40
Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)								7 years 3 days	7 years 9 months 3 days
Number of shares, options non-exercisable (non-vested)								85,671	341,159
Weighted average exercise price, options non-exercisable (non-vested)								$ 8.97	$ 36.80
Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)								8 years 6 months 7 days	8 years 9 months 25 days
Employees and Non-employee Service Provider [Member] | Minimum [Member]
Class of Stock [Line Items]
Range of Exercise price, Options Outstanding								$ 5.14	$ 12.40	12.40
Range of Exercise price, Options Outstanding									5.10
Range of Exercise price, Options Outstanding									57.50
Range of Exercise price, Options Forfeited								5.14	12.40
Range of Exercise price, Options Outstanding								5.14	10.50	5.14	12.40
Range of exercise price, options exercisable (vested)								5.14	12.40
Range of exercise price, options non-exercisable (non-vested)								5.14	10.50
Employees and Non-employee Service Provider [Member] | Maximum [Member]
Class of Stock [Line Items]
Range of Exercise price, Options Outstanding								51.30	14,657.50	14,657.50
Range of Exercise price, Options Outstanding									10.50
Range of Exercise price, Options Outstanding									14,657.50
Range of Exercise price, Options Forfeited								51.30	49.70
Range of Exercise price, Options Outstanding								51.30	51.30	$ 51.30	$ 14,657.50
Range of exercise price, options exercisable (vested)								51.30	51.30
Range of exercise price, options non-exercisable (non-vested)								$ 35.20	$ 51.30

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Dec. 22, 2022	Dec. 22, 2022	Jul. 20, 2023	Jun. 30, 2023	Jan. 12, 2023	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Purchase Price			$ 4,700,000
Conversion price					$ 1.32
Warrant to purchase shares						60,000
Exercise price of warrant						$ 13.20	$ 40.70
Series C Warrants [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Exercise price of warrant				$ 7.195
Alpha Capital [Member] | Series C Warrants [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Warrant to purchase shares	2,500,000	2,500,000
Exercise price of warrant	$ 1.65	$ 1.65
Conversion price percentage	125%	125%
Alpha Capital [Member] | Senior Convertible Debenture [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Senior convertible debenture rate	8%
Principal amount	$ 3,300,000	$ 3,300,000
Purchase Price	$ 3,000,000	$ 3,000,000
Conversion price	$ 1.32	$ 1.32

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			3 Months Ended
	Nov. 07, 2023	Oct. 03, 2023	Mar. 31, 2023
Common Stock [Member]
Subsequent Event [Line Items]
October payment in shares			841,726
October Payment [Member] | Common Stock [Member] | Alpha Capital [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
October payment in shares		128,595
License and Sponsored Research Agreements [Member] | Subsequent Event [Member] | UCL Business Limited [Member]
Subsequent Event [Line Items]
Milestone payment	$ 100,000